Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 7 | 13 | +0,26 % | ||
| REGENERON PHARMACEUTICALS | 6 | 22 | -0,28 % | ||
| HUTCHMED | 5 | 7 | +2,44 % | ||
| DYNAVAX | 4 | 4 | +0,65 % | ||
| ANAPTYSBIO | 4 | 2 | +18,28 % | ||
| INCYTE | 3 | 25 | -0,03 % | ||
| MODERNA | 3 | 16 | -1,41 % | ||
| GILEAD SCIENCES | 3 | 5 | +0,23 % | ||
| MERUS | 3 | 3 | -0,99 % | ||
| GUARDANT HEALTH | 3 | 2 | -0,96 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:17 | New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN | 1 | AASTOCKS | ||
| 04:17 | HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted | 1 | AASTOCKS | ||
| 03:59 | Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock | - | RTTNews | ||
| 03:00 | HUTCHMED's NDA For Fruquintinib-sintilimab Combo In Renal Cancer Accepted By China's NMPA | 214 | AFX News | BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment... ► Artikel lesen | |
| 02:18 | Cathie Wood's ARK sells Palantir and Roblox, buys Veracyte and Guardant | 5 | Investing.com | ||
| 02:00 | Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million | 2 | GlobeNewswire (USA) | ||
| 01:48 | HUTCHMED (China) Limited: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma | 2 | GlobeNewswire (USA) | ||
| 01:45 | HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ... | 2 | HKEx | ||
| 01:26 | Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) | 1 | Insider Monkey | ||
| 00:06 | BofA Securities raises Acadia Pharmaceuticals stock price target to $23 | 4 | Investing.com | ||
| Mi | Dynavax responds to proxy advisor calling for board change | 3 | Seeking Alpha | ||
| Mi | Cathie Wood setzt wieder auf Nvidia, auch TSMC wandert verstärkt ins Portfolio, mit Twist Bioscience wird eine Wette eingegangen und Palantir scheint der Investorin zu heiß geworden | 591 | NTG24.de | Die Börse wird oft als seriöser und kühler Ort angesehen, doch sind die Handelsplätze längst nicht frei von Emotionen. Auch hier gibt es prominente Investorinnen und Investoren, die teils wie Popsternchen... ► Artikel lesen | |
| Mi | FDA to use new review tool on Sarepta's gene therapy work | 1 | BioPharma Dive | ||
| Mi | Astria Therapeutics bei Jefferies-Konferenz: Strategische Pipeline-Einblicke | 4 | Investing.com Deutsch | ||
| Mi | ADMA BIOLOGICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates | 1 | Insider Monkey | ||
| Mi | Scotiabank Increases the Price Target for Vera Therapeutics by $10 | 3 | Insider Monkey | ||
| Mi | ANI Pharmaceuticals auf Jefferies-Konferenz: Strategisches Wachstum bei seltenen Krankheiten | 3 | Investing.com Deutsch | ||
| Mi | Dynavax-Direktoren gegenüber Deep Track-Kandidaten bevorzugt | 1 | Investing.com Deutsch | ||
| Mi | Dynavax directors favored over Deep Track slate | 1 | Investing.com |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .